LILLY (ELI) & COMPANY: Tabalumab RA Study BCDM Discontinuation

Date: December 13, 2012                                                         
For Release: Immediately 
Refer to: Media: Sonja Popp-Stahly, +1 317-655-2993,;
Investors: Phil Johnson, +1 317-655-6874, 
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration 
                             for Tabalumab                                  
FLEX-M study did not meet efficacy expectationsin an interim futility analysis;  
             discontinuation not based on safety concerns                   
INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) announced today that it will
stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of
tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy. The
decision followed a planned interim futility analysis of the FLEX-M study
investigating tabalumab, also known as LY2127399, for the treatment of patients
with moderate-to-severe RA who had an inadequate response to methotrexate
therapy. The decision was not based on safety concerns, and patients currently
enrolled in other tabalumab RA studies will continue treatment. 
The FLEX-M study was designed to support registration of tabalumab as a
potential treatment for RA, including an assessment of its effect on structural
progression. Lilly continues to evaluate tabalumab in two other Phase 3 RA
registration studies as well as an open-label extension study and several other
smaller studies. Lilly is suspending enrollment of new patients in the RA
program until additional analysis from other ongoing RA studies is completed in
early 2013. These other studies are in different patient populations. 
Phase 3 studies for systemic lupus erythematosus are ongoing and will continue
to enroll new patients. Currently, there is no evidence to suggest that
efficacy results from the FLEX-M study in RA are indicative of potential
efficacy in the lupus population. Lilly remains committed to the ongoing Phase
3 lupus program. 
"The results of this study were unexpected given the data generated in earlier
Phase II clinical studies of tabalumab," said Eiry Roberts, M.D., vice
president of autoimmune product development at Lilly. "We remain committed to
patients with rheumatoid arthritis and lupus and will move rapidly to evaluate
the impact of these data on the overall tabalumab clinical development program.
Beyond tabalumab, Lilly will continue to develop additional treatment options
for patients with autoimmune diseases." 
The decision to stop the FLEX-M study is expected to result in a fourth-quarter
charge in the range of $20 million to $35 million (pre-tax), or approximately
$0.02 per share (after-tax). The company's previously issued financial guidance
for 2012 remains unchanged. 
About the FLEX-M Study 
The FLEX-M study (study BCDM) is a Phase 3, multicenter, randomized,
double-blind, placebo-controlled study to evaluate the efficacy and safety of
tabalumab in patients with moderate-to-severe rheumatoid arthritis who had an
inadequate response to methotrexate therapy. This pivotal registration study
includes the assessment of the effect of tabalumab on structural progression. 
About BAFF and Tabalumab 
BAFF (B cell activating factor) is a cytokine that promotes B cell survival,
proliferation and activation. In the presence of excess BAFF, B cells,
including autoreactive B cells, are not appropriately eliminated by the immune
system and may therefore contribute to the development of RA by producing
autoantibodies and proinflammatory cytokines and "helping" autoreactive T
cells. BAFF exists in both membrane-bound and soluble forms. 
Tabalumab is a human immunoglobulin G subclass 4 (IgG4) monoclonal antibody
(MAb) that inhibits both membrane-bound and soluble B cell activating factor
(BAFF). Tabalumab is currently in Phase 3 development as a potential treatment
for rheumatoid arthritis and systemic lupus erythematosus. 
About Lilly's Autoimmune Pipeline 
Tabalumab is one of three potential new medicines in late-stage clinical
development for a variety of autoimmune conditions. The others are ixekizumab,
an anti-IL-17 monoclonal antibody, for psoriasis and psoriatic arthritis, and
baricitinib, a JAK1 and JAK2 inhibitor being developed in collaboration with
Incyte Corporation, for RA, psoriasis and diabetic nephropathy. 
About Lilly's Pipeline 
Lilly currently has a number of unique potential medicines in its Phase 3
clinical development pipeline, representing a variety of therapeutic areas
including diabetes (four), cancer (three), neuroscience (two), autoimmunity
(three) and cardiovascular (one).  To learn more about the molecules in Lilly's
clinical development pipeline, please visit Lilly's interactive pipeline
website available at 
About Eli Lilly and Company 
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers --
through medicines and information -- for some of the world's most urgent
medical needs. Additional information about Lilly is available at
This press release contains forward-looking statements about the potential of
tabalumab for the treatment of rheumatoid arthritis and lupus, and reflects
Lilly's current beliefs. However, as with any pharmaceutical product, there are
substantial risks and uncertainties in the process of development and
commercialization. There is no guarantee that the compound will receive
regulatory approval, or that it will be commercially successful. For further
discussion of these and other risks and uncertainties, see Lilly's filings with
the United States Securities and Exchange Commission. Lilly undertakes no duty
to update forward-looking statements. 
                                 # # #                                      
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
-0- Dec/13/2012 13:16 GMT
Press spacebar to pause and continue. Press esc to stop.